Circulating Fibrocytes in Non-small Cell Lung Cancer.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01998425

Enrollment

Registered

2013-11-28

Start date

2013-11-30

Completion date

2017-07-31

Last updated

2015-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Keywords

circulating fibrocytes, fibrocyte, NSCLC, treatment response, survival, stage

Brief summary

The investigators will collect fibrocytes (CD45+Col-1+) in patients with non-small cell lung cancer (NSCLC). The investigators hypothesize that patients with NSCLC experience expansion of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune escape in NSCLC patients.

Detailed description

Fibrocytes have been described in both mice and humans, where they bear a hematopoietic progenitor phenotype (CD45+Col-1+). Fibrocytes have previously been described in murine cancer, implicated as mediators of tumor immune escape. In this study, the investigators will collect fibrocytes including CD45+Col-1+ expression. The cells express indoleamine oxidase, which is primarily responsible for their immunosuppressive properties. The investigators hypothesize that patients with non-small cell lung cancer experience expansion of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune escape in non-small cell lung cancer patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).

Exclusion criteria

* Combination of other malignancy. * Age less than 20 years (not include 20 years). * Pregnancy.

Design outcomes

Primary

Measure	Time frame	Description
treatment response of participants by RECIST.	18 months	Correlation of circulating fibrocytes and treatment (chemotherapy, surgery, target treatment) response of patients with NSCLC.

Secondary

Measure	Time frame	Description
Survival of participants.	24 months	Correlation of circulating fibrocytes and survival (progression free survival, disease free survival and overall survival) of patients with NSCLC.

Other

Measure	Time frame	Description
Staging status of patients with NSCLC.	18 months	Correlation of circulating fibrocytes and stage of patients with NSCLC.

Countries

Taiwan

Contacts

Primary ContactFu-Tsai Chung

vikingchung@yahoo.com.tw

Outcome results